Hepatic Fibrosis PIIINP detection kit for chemiluminescence immunoassay (CLIA) system
Home » Products » Diagnostic Reagents » Hepatic Fibrosis PIIINP detection kit for chemiluminescence immunoassay (CLIA) system


Hepatic Fibrosis PIIINP detection kit for chemiluminescence immunoassay (CLIA) system

Procollagen III, N-terminal propeptide (PIIINP) is used as a biomarker for increased collagen III-synthesis.


  • DR1031

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button


The kit has been designed for the quantitative determination of Pepsinogen III N Terminal Peptide PNPin human serum. 

The method can be used for samples over the range of 4-700 ng/mL

Pepsinogen III N Terminal Peptide (PNP) quantitative detection kit (CLIA) (hereinafter referred to  as the kit) is used for in vitro quantitative detection of PNP concentration in human serum. 

PNP can effectively reflect the synthesis of collagen type Ⅲ. Its serum levels consistent with the degree of  liver fibrosis and significantly correlated with serum γ- globulin levels. 

PNP level is closely  related with the activity of liver fibrosis which is valuable in the early diagnosis of liver fibrosis  and the prognosis of chronic liver disease. 

PNP in normal liver is the amino terminus polypeptide generated by the amino-terminal peptide  cleavage which is secreted by the PIII out of the liver cell before deposition. During this process,  PNP and type N-terminal peptide showed equal concentration, and entered into the blood  circulation. Therefore, PNP concentration can be an indicator to detect PNP synthesis.  

PNP can be divided into four parts by chromatography: amino-terminal propeptide of 50KD,  Coll of l0 KD (degradation part of the former), and the other two parts are the polymer propeptide  dimer. With the development of liver fibrosis, PNP of 50KD rises, and is with a positive  correlation with the degree of cirrhosis, such as cirrhosis of the liver and liver fibrosis caused by  virus and alcohol . 

Therefore, LN, CIV, HA and PNP become indicators for judgment of the  severity of liver disease, to identify the presence or absence of cirrhosis and make prognosis.  PNP diagnosis is not initially detected, but in detecting the onset of a sustainable process. Diagnosis of liver fibrosis has been dependent on liver biopsy diagnosis, which has a number of  significant deficiencies, for example, being traumatic, being difficult to repeat biopsies, certain  complications (1/3 patients with pain; 0.3% patients with serious complications, including bleeding,  pneumothorax, colon and gallbladder perforation; 0.03% mortality). Lesions in the liver are uneven,  and there are differences between the viewer himself and between different viewers. Sample length  is not enough (length <20mm and <10 pcs of portal area) which is prone to underestimate and  broken specimens or subcapsular hepatic fibrosis can cause artifacts. 



Zecen Biotech CO., LTD. founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents.
Leave a Message




Tel: +86-17751649333
Phone: +86-523-86817711
Add: Building G62, Phase 4 Plant, China Medical City, Taizhou City, Jiangsu Province
​Copyright © 2023 Zecen Biotech CO., LTD. All rights reserved. | Sitemap | Privacy Policy | Supported by leadong.com